JP6689078B2 - 超高純度なテトラヒドロカンナビノール−１１−酸 - Google Patents

超高純度なテトラヒドロカンナビノール−１１−酸 Download PDF

Info

Publication number
JP6689078B2
JP6689078B2 JP2015557221A JP2015557221A JP6689078B2 JP 6689078 B2 JP6689078 B2 JP 6689078B2 JP 2015557221 A JP2015557221 A JP 2015557221A JP 2015557221 A JP2015557221 A JP 2015557221A JP 6689078 B2 JP6689078 B2 JP 6689078B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
acid
fibrosis
receptor
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015557221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510340A (ja
JP2016510340A5 (enExample
Inventor
テッパー、マーク
エー． フレイ、ディーン
エー． フレイ、ディーン
ゴーデル、デイビッド
イー． ライニキー、カール
イー． ライニキー、カール
Original Assignee
コーバス ファーマシューティカルズ インク．
コーバス ファーマシューティカルズ インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーバス ファーマシューティカルズ インク．, コーバス ファーマシューティカルズ インク． filed Critical コーバス ファーマシューティカルズ インク．
Publication of JP2016510340A publication Critical patent/JP2016510340A/ja
Publication of JP2016510340A5 publication Critical patent/JP2016510340A5/ja
Application granted granted Critical
Publication of JP6689078B2 publication Critical patent/JP6689078B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2015557221A 2013-02-12 2014-02-12 超高純度なテトラヒドロカンナビノール−１１−酸 Expired - Fee Related JP6689078B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361763630P 2013-02-12 2013-02-12
US61/763,630 2013-02-12
US201361837743P 2013-06-21 2013-06-21
US61/837,743 2013-06-21
PCT/US2014/016050 WO2014127016A2 (en) 2013-02-12 2014-02-12 Ultrapure tetrahydrocannabinol-11-oic acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018178162A Division JP2019031505A (ja) 2013-02-12 2018-09-22 超高純度なテトラヒドロカンナビノール−１１−酸

Publications (3)

Publication Number Publication Date
JP2016510340A JP2016510340A (ja) 2016-04-07
JP2016510340A5 JP2016510340A5 (enExample) 2017-03-16
JP6689078B2 true JP6689078B2 (ja) 2020-04-28

Family

ID=51354671

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015557221A Expired - Fee Related JP6689078B2 (ja) 2013-02-12 2014-02-12 超高純度なテトラヒドロカンナビノール−１１−酸
JP2018178162A Pending JP2019031505A (ja) 2013-02-12 2018-09-22 超高純度なテトラヒドロカンナビノール−１１−酸
JP2021133797A Pending JP2021185166A (ja) 2013-02-12 2021-08-19 超高純度なテトラヒドロカンナビノール−１１−酸

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018178162A Pending JP2019031505A (ja) 2013-02-12 2018-09-22 超高純度なテトラヒドロカンナビノール−１１−酸
JP2021133797A Pending JP2021185166A (ja) 2013-02-12 2021-08-19 超高純度なテトラヒドロカンナビノール−１１−酸

Country Status (9)

Country Link
US (8) US20150141501A1 (enExample)
EP (2) EP3851101A1 (enExample)
JP (3) JP6689078B2 (enExample)
KR (2) KR20160002709A (enExample)
CN (2) CN110946854A (enExample)
AU (2) AU2014216440B2 (enExample)
BR (1) BR112015019180A8 (enExample)
CA (1) CA2900982C (enExample)
WO (1) WO2014127016A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160002709A (ko) 2013-02-12 2016-01-08 코버스 파마수티컬스, 아이엔씨. 초고순도 테트라하이드로카나비놀-11-오익산
AU2017258765A1 (en) * 2016-04-29 2018-11-29 Corbus Pharmaceuticals, Inc. Methods for the treatment of infection
RU2019103297A (ru) * 2016-07-11 2020-08-11 Интек Фарма Лтд. Гастроретентивные составы для перорального введения и пути их применения
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
US20210284621A1 (en) * 2018-05-31 2021-09-16 Corbus Pharmaceuticals, Inc. Cannabinoids and uses thereof
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. CANNABIGEROL SYNTHESIS
US20200121614A1 (en) * 2018-10-18 2020-04-23 Bluegrass Farmacueticals, LLC Cannabinoid-infused transparent hydrogel skin patch
WO2020183456A1 (en) * 2019-03-10 2020-09-17 Bol Pharma Ltd. Cannabinoid combinations for treating chronic pain in dialysis patients
WO2021072325A1 (en) 2019-10-11 2021-04-15 Corbus Pharmaceuticals, Inc. Compositions of ajulemic acid and uses thereof
AR123027A1 (es) * 2020-07-21 2022-10-26 Np Pharma Holdings Llc Composiciones y métodos de cannabinoides para el tratamiento del dolor y la inflamación de las articulaciones

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US8586767B2 (en) 1999-03-22 2013-11-19 Craig Rick Travis Method for treatment of HIV and diseases of immune dysregulation
US6974835B2 (en) 2000-05-17 2005-12-13 Indevus Pharmaceuticals, Inc. Methods for decreasing cell proliferation based on (3r,4r)-Δ8-tetrahydrocannabinol-11-oic acids
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
EP1409473A2 (en) * 2001-03-07 2004-04-21 Websar Innovations Inc. CONVERSION OF CBD TO $g(D)?8 -THC AND $g(D)?9 -THC
EP1567513A2 (en) * 2002-12-04 2005-08-31 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical copositions
IL153277A0 (en) * 2002-12-04 2003-07-06 Pharmos Corp High enantiomeric purity dexanabinol for pharmaceutical compositions
AU2003297074A1 (en) 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
WO2004058251A1 (en) 2002-12-19 2004-07-15 University Of Massachusetts Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US20050070596A1 (en) 2003-05-12 2005-03-31 David Baker Methods for treatment of inflammatory diseases using CT-3 or analogs thereof
US20050009903A1 (en) * 2003-06-10 2005-01-13 Martin Billy R. CB2-selective cannabinoid analogues
KR20080000660A (ko) 2005-04-21 2008-01-02 오르펀 메디칼, 인크. 초순수 4-메틸피라졸의 제조 방법
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070037873A1 (en) 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
WO2007032962A2 (en) 2005-09-09 2007-03-22 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
US20070099988A1 (en) * 2005-10-31 2007-05-03 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
PT1903866E (pt) 2005-11-07 2016-06-09 Murty Pharmaceuticals Inc Distribuição melhorada de tetra-hidrocanabinol
US20080054300A1 (en) * 2006-06-30 2008-03-06 Philip Gene Nikkel Body contact structure and method for the reduction of drain lag and gate lag in field effect transistors
US8058227B2 (en) 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
US8044071B2 (en) 2007-10-18 2011-10-25 Abbott Laboratories Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist
WO2009158499A2 (en) 2008-06-25 2009-12-30 University Of North Texas Health Science Center At Fort Worth Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
WO2012048045A1 (en) 2010-10-05 2012-04-12 Jb Therapeutics, Inc. Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
US20120309820A1 (en) * 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
KR20160002709A (ko) 2013-02-12 2016-01-08 코버스 파마수티컬스, 아이엔씨. 초고순도 테트라하이드로카나비놀-11-오익산
US20150328198A1 (en) 2014-05-16 2015-11-19 The University Of North Carolina At Chapel Hill Methods of treating methicillin-resistant staphylococcus aureus (mrsa) using ppar-gamma agonists

Also Published As

Publication number Publication date
WO2014127016A2 (en) 2014-08-21
US9820964B2 (en) 2017-11-21
CA2900982C (en) 2021-06-01
US10085964B2 (en) 2018-10-02
WO2014127016A3 (en) 2015-11-26
EP2956133A2 (en) 2015-12-23
US20170071899A1 (en) 2017-03-16
BR112015019180A2 (pt) 2017-07-18
AU2018258159B2 (en) 2020-01-02
JP2021185166A (ja) 2021-12-09
US9801849B2 (en) 2017-10-31
US20190091200A1 (en) 2019-03-28
KR20190139327A (ko) 2019-12-17
CN105228613A (zh) 2016-01-06
JP2016510340A (ja) 2016-04-07
BR112015019180A8 (pt) 2018-01-30
EP3851101A1 (en) 2021-07-21
US20170071898A1 (en) 2017-03-16
CA2900982A1 (en) 2014-08-21
CN110946854A (zh) 2020-04-03
US20200093784A1 (en) 2020-03-26
US20220117931A1 (en) 2022-04-21
US11052066B2 (en) 2021-07-06
EP2956133A4 (en) 2016-12-21
AU2018258159A1 (en) 2018-11-22
US20170071900A1 (en) 2017-03-16
KR20160002709A (ko) 2016-01-08
AU2014216440B2 (en) 2018-08-09
US20180177757A1 (en) 2018-06-28
US20150141501A1 (en) 2015-05-21
US10154986B2 (en) 2018-12-18
AU2014216440A1 (en) 2015-08-20
JP2019031505A (ja) 2019-02-28
US10369131B2 (en) 2019-08-06

Similar Documents

Publication Publication Date Title
US11052066B2 (en) Ultrapure tetrahydrocannabinol-11-oic acids
JP6082347B2 (ja) ポリ不飽和長鎖ケトンを用いるリウマチ性関節炎の治療
WO2009007697A1 (en) New pharmaceutical formulation comprising cannabidiol and tetrahydrocannabidivarin
JP5837481B2 (ja) 糸球体腎炎治療
EA022166B1 (ru) Синтетические тритерпеноиды и их применение в лечении заболеваний
Lin et al. Supramolecular nanofiber of indomethacin derivative confers highly cyclooxygenase-2 (COX-2) selectivity and boosts anti-inflammatory efficacy
KR102512891B1 (ko) 중추 신경계 장애를 치료하기 위한 벤조산리튬의 용도
CN116650490A (zh) 化合物mt-1207在降低尿酸方面的应用
CN117242076A (zh) 基于噻吩的化合物及其作为bckdk抑制剂的用途
HK40026965A (en) Ultrapure tetrahydrocannabinol-11-oic acids
JP2022506548A (ja) 化合物の抗ｐｃｓｋ９（抗プロタンパク質変換酵素スブチリシン ケキシン９型）ナノ製剤および心血管疾患の治療および／または予防におけるその使用方法
JP2020033272A (ja) 過活動膀胱の予防又は改善剤
CN108546268B (zh) 用于治疗动脉粥样硬化的化合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200103

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200407

R150 Certificate of patent or registration of utility model

Ref document number: 6689078

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees